ARTICLE | Company News
EC approves Kevzara, Skilarence
June 27, 2017 11:38 PM UTC
The European Commission approved two autoimmune drugs: Skilarence (LAS41008) from Almirall S.A. (Madrid:ALM) and Kevzara sarilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY).
The EC approved Skilarence to treat moderate to severe chronic plaque psoriasis, both for first-line induction and long-term maintenance treatment. Almirall plans to launch the drug next quarter in all EU member states, Iceland and Norway. Skilarence is an oral dimethyl fumarate targeting nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)...